Investigators Levi & Korsinsky examine Pacific Biosciences of California's Q1 2024 results and reduced guidance, while insider Jonathan Slonin sells Pacira BioSciences shares.

Investigators Levi & Korsinsky are examining Pacific Biosciences of California (NASDAQ: PACB) following poor Q1 2024 results and reduced full-year guidance. Insider Jonathan Slonin has sold Pacira BioSciences (NASDAQ: PCRX) shares, with his total ownership down to $1,890,855.35. Pacific Biosciences of California has seen changes in share ownership by major investors in Q1 2021. Analysts have issued various ratings and price targets for Pacific Biosciences of California and Pacira BioSciences, with a consensus target price of $41.44 for Pacira BioSciences.

August 05, 2024
6 Articles